Investigations of the impacts of KCNJ5 mutations on symptoms, prognosis, and even systemic target organ damage, including cardiovascular structure and function, and metabolic disorders, may affect the treatment strategy of patients. This evidence concerns the gene KCNJ5 and metabolic disease.